$Moleculin Biotech(MBRX.US)$Moleculin Announces Commencement of Nih-Funded Phase 2 Clinical Trial of Stat3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)
$Moleculin Biotech(MBRX.US)$ NEWS Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin The issuance of the U.S. Patent for Lipid-Based Delivery Technology for Annamycin provides composition protection until 2040, with the potential for extension, enhancing the Company's intellectual property portfolio. Annamycin, the next-generation anthracycline developed by Moleculin, has demonstrated promising results in clinical studies, showing non-cardiotoxic...
$Moleculin Biotech(MBRX.US)$Reuters· 1 min ago Moleculin Reports Higher Aml Complete Remission (Cr) Rates and Significant Durability With Additional Interim Subject Data
Moleculin Biotech股票討論區
Moleculin 完成與 FDA 關於 AML 治療安納胺素的第二階段結束會議
Moleculin Biotech 已完成與美國食品藥物管理局(FDA)的第二期結束會議,以進行一次 1B/2 期臨床試驗,用於治療 AML(Mb-106)的安納米辛與細胞拉賓結合治療 AML(Mb-106)。會議專注於檢討臨床數據並規劃下一步,預計將在 2024 年第三季度正式結果。中期結果顯示,在 22 名入學者中,45% 成為綜合完全忽略...
Moleculin 宣布安納米辛基脂分配技術的美國專利發行通知
NEWS
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
The issuance of the U.S. Patent for Lipid-Based Delivery Technology for Annamycin provides composition protection until 2040, with the potential for extension, enhancing the Company's intellectual property portfolio.
Annamycin, the next-generation anthracycline developed by Moleculin, has demonstrated promising results in clinical studies, showing non-cardiotoxic...
Moleculin Reports Higher Aml Complete Remission (Cr) Rates and Significant Durability With Additional Interim Subject Data
新聞
歐洲藥物管理局 (EMA) 授予孤兒藥物指定用於分子林治療急性骨髓性白血病(AML)
暫無評論